Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 7/7/2020
SIETES contiene 93061 citas

 1 a 20 de 41 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Fuentes Camps I, Rodríguez A, Agustí A. Non-commercial vs. commercial clinical trials: a retrospective study of the applications submitted to a research ethics committee . Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102808]
3. Cita con resumen
Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn S, Dreyer AN. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol 2017;83:884-93. [Ref.ID 101970]
4.Tiene citas relacionadas Cita con resumen
Eichler H-G, Hurts H, Broich K, Rasi G. Drug regulation and pricing — Can regulators influence affordability?. N Engl J Med 2016;374:1807-9. [Ref.ID 100113]
6.Tiene citas relacionadas
Rothwell PM. Blood pressure in acute stroke: which questions remain?. Lancet 2015;385:582-5. [Ref.ID 98797]
7. Cita con resumen
Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW, De Bruin ML. Number of patients studied prior to approval of new medicines: database analysis. PLOS Medicine 2013;10:1. [Ref.ID 95146]
8.Tiene citas relacionadas Cita con resumen
Gale E. Post-marketing studies of new insulins: science or sales?. BMJ 2012;344:24-7. [Ref.ID 93248]
9.Tiene citas relacionadas Cita con resumen
11. Cita con resumen
Shaughnessy A. Old drugs, new tricks. BMJ 2011;342:360-1. [Ref.ID 90211]
12. Cita con resumen
Strahlman E, Rockhold F, Freeman A. Public disclosure of clinical research. Lancet 2009;373:1319-20. [Ref.ID 85657]
14. Cita con resumen
Clark DWJ, Coulter DM, Besag FMC. Randomized controlled trials and assessment of drug safety. Drug Saf 2008;31:1057-61. [Ref.ID 84722]
15. Cita con resumen
Cohen AF. Methods in clinical pharmacology - a tale of two worlds. Br J Clin Pharmacol 2008;66:585-7. [Ref.ID 84390]
16. Cita con resumen
Lenzer J. Truly independent research?. BMJ 2008;337:602-6. [Ref.ID 83973]
17. Cita con resumen
Cooper AJP, Lettis S, Chapman CL, Evans SJW, Waller PC, Shakir S, Payvandi N, Murray AB. Developing tools for the safety specification in risk management plans: lessons learned from a pilot project. Pharmacoepidemiol Drug Saf 2008;17:45-454. [Ref.ID 82982]
18. Cita con resumen
Anónimo. New rimonabant recommendations made in Argentina. Scrip 2007;3285:16. [Ref.ID 80725]
19. Cita con resumen
Day RO, Williams KM. Open-label extension studies: do they provide meaningful information on the safety of new drugs?. Drug Saf 2007;30:93-105. [Ref.ID 79290]
20. Cita con resumen
Psaty BM, Weiss NS. NSAID trials and the choice of comparators - questions of public health importance. N Engl J Med 2007;356:328-30. [Ref.ID 78942]
Seleccionar todas
 1 a 20 de 41 siguiente >>